Research Gynecologic Cancer Ovarian Cancer
Ovarian cancer is one of the leading causes of cancer death among women, with nearly 20,000 new diagnoses each year and around 12,740 deaths from the disease estimated in 2024, according to the American Cancer Society
Gynecologic Cancer Endometrial Cancer Clinical Trials
According to her race medals, Charlotte Butler has walked all over the place. On trails in Spain, France, Ireland, and the Netherlands, not to mention the Rocky Mountains and other spots in the U.S.
Research Press Releases Gynecologic Cancer Endometrial Cancer
The results of a multisite clinical trial overseen by University of Colorado Cancer Center member Bradley Corr, MD, could offer new hope to patients with metastatic and recurrent uterine cancer, also known as endometrial cancer.
Research Gynecologic Cancer Magazine Ovarian Cancer
Ovarian cancer is a growing area of research at the University of Colorado Cancer Center. A newly formed Ovarian Cancer Innovations Group, envisioned by Saketh Guntupalli, MD, and led by Kian Behbakht, MD, MBA, is taking a multipronged approach to studying the disease.
Research Community Awareness Gynecologic Cancer Vaccinations Cervical Cancer
Even as exciting developments are happening in cervical cancer research, an estimated 14,100 new cases of invasive cervical cancer will be diagnosed in the United States this year.
Gynecologic Cancer Vaccinations Cervical Cancer
January is Cervical Cancer Awareness Month, and CU Cancer Center member Lindsay Brubaker, MD, wants everyone to be aware of the relationship between cervical cancer and the human papillomavirus (HPV), a sexually-transmitted disease that causes the vast majority of cervical cancers. The current HPV vaccine protects against seven predominant strains of the virus that cause cancer, as well as the two that cause genital warts.
Press Coverage Gynecologic Cancer
Peyton taught the world that ovarian cancer doesn’t just strike mothers and grandmothers. “She’s brought so much awareness to the disease through her advocacy,” said CU Cancer Center member Saketh Guntupalli, MD.
Research Gynecologic Cancer Ovarian Cancer
After nearly four years of work, a group of researchers and clinicians from the University of Colorado (CU) published a paper this week in the Clinical Cancer Research that shares findings from research looking at how the composition of ovarian cancer tumors changes during chemotherapy and contributes to therapeutic response.
Research Gynecologic Cancer Cervical Cancer
Last month the American Cancer Society (ACS) released updated guidelines for cervical cancer screening. The most notable change in guidelines is the changes in the age to begin screening. Per the new guidelines, it is recommended that cervical cancer screening begin at age 25. Previously, the starting age for screening was 21.
Philanthropy Gynecologic Cancer Cancer Ovarian Cancer
In July 2019, Emily McClintock Addlesperger was on vacation in Maine with her husband, Jason, when she felt sick and was airlifted to Portland with internal bleeding. A tumor on her ovary had burst. It was Monday. On Saturday, she passed away. Emily was 44 years old.
Gynecologic Cancer Clinical Research
Brad Corr’s inspiration to pursue a medical career came on the ski slopes of Big Sky, Montana.
This July, University of Colorado Cancer Center investigator, Saketh Guntupalli, MD, assumes the role of Division Chief of the CU School of Medicine Department of Obstetrics and Gynecology Division of Gynecologic Oncology, with a mission to increase the excellence of clinical care, train the next generation of physician-scientists, and move the needle on gynecologic cancer research. Guntupalli takes over a program that already boasts 15-20 percent improved survival rates over national averages for some cancers including uterine cancer.
Sexual health can be an uncomfortable subject after completing cancer treatment, but is an important quality of life issue. A University of Colorado Cancer Center study presented at the 2019 American Society of Clinical Oncology (ASCO) conference in Chicago highlights the unmet need of interventions to improve and maintain optimal sexual health.
In women at high risk for ovarian cancer, the common prevention strategy is to remove fallopian tubes and ovaries as soon as the woman is done having a family – the sooner the better. But this initiates menopause and along with it higher risk of cardiovascular disease, osteoporosis, sexual side-effects, and perhaps even Alzheimer’s disease. A recent University of Colorado Cancer Center review in the International Journal of Gynecologic Cancer suggests a way young, high-risk women can reduce risk while leaving menopause for later: the technique known as salpingectomy removes the fallopian tubes while leaving ovaries intact.
Cure Today
July 12, 2024
University of Colorado Cancer Center member Dr. Steven Thorpe emphasizes the collaborative nature of treating soft tissue and bone sarcomas, highlighting the multidisciplinary efforts at CU School of Medicine's Department of Orthopedics and Children’s Hospital Colorado. He underscores the goal of not only curing the disease but also preserving function through advanced surgical techniques and modern therapies, ensuring patients maintain quality of life post-treatment. Thorpe stresses the importance of long-term outcomes, tailoring treatments to support patients’ aspirations beyond their cancer journey, especially for pediatric cases.
OncLive
July 08, 2024
CU Cancer Center member S. Lindsey Davis, MD, highlighted that the combination therapy of sapanisertib and alisertib showed marginal clinical benefit for patients with advanced solid tumors, correlative analyses suggested that apoptotic response and tumor immune cell infiltrate might influence clinical outcomes. The phase 1b study's expansion cohort indicated some positive outlying responses among patients and underscore the need for further research to tailor treatments for standout patients and explore rational combinations to enhance efficacy.
News Medical
June 19, 2024
A new study led by University of Colorado Cancer Center member Marco Del Chiaro, MD, PhD, reveals that nearly 5% of pancreatic adenocarcinoma patients achieved a pathological complete response (pCR) after pre-surgical chemotherapy or chemoradiotherapy. This significant finding indicates that patients with pCR have a 63% five-year survival rate, compared to 30% for those without pCR, suggesting the potential for tailored treatments to improve outcomes.
Cancer Network
June 14, 2024
In a conversation at the 2024 European Hematology Association Congress, CU Cancer Center member Manali Kamdar, MD, discussed potential future research on lisocabtagene maraleucel (liso-cel; Breyanzi) for mantle cell lymphoma (MCL) and other lymphoma subgroups. She highlighted findings from the phase 1 TRANSCEND NHL 001 trial, noting improved efficacy and safety in patients with fewer prior therapies and non-refractory disease, suggesting liso-cel's utility in earlier treatment lines and specific lymphoma subgroups.
Greg Glasgow
